ABSTRACT Dupilumab has emerged as a promising treatment for inflammatory dermatitis in some epidermal differentiation disorders (EDDs, formerly known as ichthyosis). We report a 5‐month‐old female with recurrent generalized skin peeling and erythematous plaques since birth that were refractory to multiple topical therapies; she was diagnosed with ALOXE3 ‐associated nonsyndromic epidermal differentiation disorder ( ALOXE3 ‐nEDD) by whole exome sequencing. Following initiation of dupilumab, she experienced near‐complete resolution of erythematous plaques within 9 months and improvement of pruritus, with sustained response over 2 years of treatment. This case highlights dupilumab as a potential treatment for inflammatory dermatitis associated with ALOXE3 ‐nEDD and similar EDDs.
Hsing‐Jou Su, Rosalynn M. Nazarian, Elena B. Hawryluk. Successful Treatment of Inflammatory Dermatitis Associated With ALOXE3 Nonsyndromic Epidermal Differentiation Disorder Using Dupilumab. // Pediatric Dermatology. – 2026. – DOI: 10.1111/pde.70350. – URL: https://onlinelibrary.wiley.com/doi/10.1111/pde.70350?af=R
Hsing‐Jou Su, Rosalynn M. Nazarian, & Elena B. Hawryluk (2026). Successful Treatment of Inflammatory Dermatitis Associated With ALOXE3 Nonsyndromic Epidermal Differentiation Disorder Using Dupilumab. Pediatric Dermatology. https://doi.org/10.1111/pde.70350
Hsing‐Jou Su, et al. “Successful Treatment of Inflammatory Dermatitis Associated With ALOXE3 Nonsyndromic Epidermal Differentiation Disorder Using Dupilumab.” Pediatric Dermatology, 2026. doi:10.1111/pde.70350.
@article{Su2026,
title = {Successful Treatment of Inflammatory Dermatitis Associated With ALOXE3 Nonsyndromic Epidermal Differentiation Disorder Using Dupilumab},
author = {Su, Hsing‐Jou and Nazarian, Rosalynn M. and Hawryluk, Elena B.},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70350},
url = {https://onlinelibrary.wiley.com/doi/10.1111/pde.70350?af=R}
}